Erythrocyte transketolase activity and guandino compounds in hemodialysis patients

Erythrocyte transketolase activity and guanidino compounds in hemodialysis patientsBackgroundThe toxic effects of guanidino compounds on enzymatic activity in uremic patients are known. Thus, we determined the hemodialysis (HD) impact on this toxicity.MethodsThe erythrocyte transketolase activity (ETAK), total guanidino compounds (TGCs), and guanidinosuccnic acid (GSA) levels in plasma were compared before, after 5 hours of HD, and at 12 and 24 hours from the end of HD. Thirty-seven HD patients (28 to 49 years old) with primary glomerulopathies participated in this study. Thirty healthy volunteers (HVs) served as controls.ResultsAt the beginning of this study, ETKA was in uremics (1.94 ± 0.45) than in HVs (2.59 ± 0.26). The TGC and GSA plasma levels were higher (26.07 ± 5.34 and 4.5 ± 1.22) than in HVs (10.41 ± 1.42 and 0.76 ± 0.09,P < 0.001), respectively. After five hours of HD, the ETKA increased to 2.49 ± 2.02 (P < 0.001). The plasma levels TGC decreasd to 12.56 ± 2.02 (P < 0.001) and the GSA to 2.12 ± 0.68 (P < 0.001). After 12 and 24 hours from the end of HD, the ETKA decreased to 2.25 ± 0.56 and 2.09 ± 0.49 (P 0.001), respectively. The plasma levels for TGC and GSA both increased: TGC to 19.39 ± 3.67 and 25.68 ± 4.61 (P < 0.001), respctively; GSA to 3.49 ± 1.11 and 4.53 ± 1.12 (P < 0.001), respectively.ConclusionThere was no significant correlation between ETKA and the plasma levels of the examined toxins. By removing the guanidino compounds, HD temporarily decreases the inhibition of EKTA, diminishing other metabolic disturbances connected with pentose phosphate cycle.